ASCA: Surgery Centers Receive Letters Warning About Compounded Drugs

Surgery centers have reported to ASCA that they have received letters from law firms representing drug manufacturers, warning about the use of compounded drug products over commercially produced drugs, according to an ASCA report.

ASCA has contacted the FDA to determine whether the statements in the letters are accurate. ASCA asks surgery centers receiving such letters to contact Steve Miller at smiller@ascassociation.org.

Related Articles About ASC Supply Chain:
Precision Spine Receives FDA Clearance for Minimally Invasive Access System
Lutronic Receives FDA Clearance for Phototherapy System
Ethicon Initiates Recall of Select Surgiflo Hemostatic Kits

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers